Skip to main content
Clinical Trials/NCT01570517
NCT01570517
Completed
Not Applicable

Evaluation of the DC Devices IASD System in the Treatment of Patients With Heart Failure With Preserved Ejection Fraction

Corvia Medical3 sites in 3 countries11 target enrollmentMay 2012
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Corvia Medical
Enrollment
11
Locations
3
Primary Endpoint
Serious Adverse Device Events
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.

Detailed Description

The study was a multi-center, non-randomized feasibility evaluation of the IASD System at three centers in three countries (Denmark, Australia, and Czech Republic). Relevant ethics committee and competent authority approvals were obtained. The study was conducted in accordance with the Declaration of Helsinki. The protocol required the treatment of a minimum of 5 patients, and allowed up to twenty patients to be enrolled. The primary objective of the trial was to evaluate the safety and potential benefits of the IASD Device System in the treatment of patients with symptomatic heart failure with preserved ejection fraction, despite optimal medical management.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
December 2014
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Corvia Medical
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of HFpEF
  • Ejection Fraction of at least 45%
  • Imaging and hemodynamic evidence of HFpEF
  • History of exercise intolerance
  • Symptomatic despite optimal medical management
  • Signed study specific informed consent

Exclusion Criteria

  • History of thromboembolic events
  • Significant structural heart disease or coronary artery disease
  • Contraindicated to study required medication
  • Right ventricular dysfunction
  • History of greater than mild restrictive or obstructive lung disease
  • Life expectancy less than one year for non-cardiovascular reasons
  • Known or suspected allergy to implant material
  • Fertile women

Outcomes

Primary Outcomes

Serious Adverse Device Events

Time Frame: One month

Study Sites (3)

Loading locations...

Similar Trials